Drivers of age-related inflammation and strategies for healthspan extension

Immunological Reviews

Volumn 265, Issue 1, 2015, Pages 63-74

  Goldberg, Emily L ^a   Dixit, Vishwa Deep ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipose tissue; Cytokines; IL 1; IL 18; Inflammasome; Macrophage; NLRP3; Sarcopenia; Senescence

Indexed keywords

COMPLEMENT; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; POLYUNSATURATED FATTY ACID; CARRIER PROTEIN; NLRP3 PROTEIN, HUMAN;

AGE RELATED INFLAMMATION; AGING; ATHEROSCLEROSIS; CALORIC RESTRICTION; CHRONIC DISEASE; COGNITIVE DEFECT; ENZYME ACTIVATION; FRAILTY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INVOLUTION; KETOGENIC DIET; LIFE EXTENSION; METABOLIC DISORDER; NERVOUS SYSTEM INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL DISEASE; PRIORITY JOURNAL; REVIEW; THYMIC INVOLUTION; THYMUS; ANIMAL; BONE MARROW CELL; IMMUNOLOGY; METABOLISM;

AGING; ANIMALS; CARRIER PROTEINS; CASPASE 1; HUMANS; INFLAMMATION; INTERLEUKIN-1; MYELOID CELLS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84927748959     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12295     Document Type: Review

References (90)

1. NIA. Global health and aging, 2011. Available from http://wwwnianihgov/sites/default/files/global_health_and_agingpdf.
2. Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. Curr Opin Immunol 2014;29:23-28.
3. CDC. Hear Disease and Stroke Prevention. Addressing the Nation's Leading Killers: At a Glance 2011, 2011. Available from http://wwwcdcgov/chronicdisease/resources/publications/AAG/dhdsphtm.
4. Medicare spending and financing fact sheet. Kaiser Family Foundation, 2011. Available from http://kfforg/medicare/fact-sheet/medicare-spending-and-financing-fact-sheet/.
5. Fakhouri TH, Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among older adults in the United States, 2007-2010. NCHS data brief, no 106, 2012.
6. Pedersen M, et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 2003;124:495-502.
7. Ferrucci L, et al. The origins of age-related proinflammatory state. Blood 2005;105:2294-2299.
8. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 2006;83:447S-455S.
9. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am 2003;23:15-39.
10. Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 2002;50:1268-1271.
11. Franceschi C, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007;128:92-105.
12. Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol 2012;22:R733-R740.
13. Franceschi C, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000;908:244-254.
14. Goto M. Inflammaging (inflammation + aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Bioscience trends 2008;2:218-230.
15. Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830.
16. Nagareddy PR, et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab 2014;19:821-835.
17. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 2014;69(Suppl):S4-S9.
18. Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 2013;39:432-441.
19. Bauernfeind FG, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009;183:787-791.
20. Barker BR, Taxman DJ, Ting JP. Cross-regulation between the IL-1beta/IL-18 processing inflammasome and other inflammatory cytokines. Curr Opin Immunol 2011;23:591-597.
21. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674-677.
22. Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-1361.
23. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-241.
24. Vandanmagsar B, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011;17:179-188.
25. Guarda G, et al. Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011;186:2529-2534.
26. Boehmer ED, Goral J, Faunce DE, Kovacs EJ. Age-dependent decrease in Toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression. J Leukoc Biol 2004;75:342-349.
27. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002;169:4697-4701.
28. Krone CL, Trzcinski K, Zborowski T, Sanders EA, Bogaert D. Impaired innate mucosal immunity in aged mice permits prolonged Streptococcus pneumoniae colonization. Infect Immun 2013;81:4615-4625.
29. An LL, et al. Complement C5a potentiates uric acid crystal-induced IL-1beta production. Eur J Immunol 2014;44:3669-3679.
30. Asgari E, et al. C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood 2013;122:3473-3481.
31. Laudisi F, et al. Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1beta release. J Immunol 2013;191:1006-1010.
32. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454:428-435.
33. Youm YH, et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab 2013;18:519-532.
34. Heneka MT, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013;493:674-678.
35. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. Nat Immunol 2013;14:986-995.
36. Hashimoto D, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013;38:792-804.
37. Schulz C, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012;336:86-90.
38. Lavin Y, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014;159:1312-1326.
39. Youm YH, et al. The Nlrp3 inflammasome promotes age-related thymic demise and immunosenescence. Cell Rep 2012;1:56-68.
40. Dixit VD. Impact of immune-metabolic interactions on age-related thymic demise and T cell senescence. Semin Immunol 2012;24:321-330.
41. Samstad EO, et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J Immunol 2014;192:2837-2845.
42. Zheng F, Xing S, Gong Z, Xing Q. NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis. Heart Lung Circ 2013;22:746-750.
43. Wang L, Qu P, Zhao J, Chang Y. NLRP3 and downstream cytokine expression elevated in the monocytes of patients with coronary artery disease. Arch Med Sci 2014;10:791-800.
44. Evans DA, et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989;262:2551-2556.
45. Bianca VD, Dusi S, Bianchini E, Dal Pra I, Rossi F. Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J Biol Chem 1999;274:15493-15499.
46. Halle A, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008;9:857-865.
47. Grathwohl SA, et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 2009;12:1361-1363.
48. Fontana L, et al. Identification of a metabolic signature for multidimensional impairment and mortality risk in hospitalized older patients. Aging Cell 2013;12:459-466.
49. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014;311:806-814.
50. Yang H, Youm YH, Dixit VD. Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution. J Immunol 2009;183:3040-3052.
51. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006;2:35-43.
52. Blaum CS, Xue QL, Michelon E, Semba RD, Fried LP. The association between obesity and the frailty syndrome in older women: the Women's Health and Aging Studies. J Am Geriatr Soc 2005;53:927-934.
53. Feuerer M, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009;15:930-939.
54. + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 2009;15:914-920.
55. Winer S, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009;15:921-929.
56. Lumeng CN, et al. Aging is associated with an increase in T cells and inflammatory macrophages in visceral adipose tissue. J Immunol 2011;187:6208-6216.
57. Youm YH, Adijiang A, Vandanmagsar B, Burk D, Ravussin A, Dixit VD. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011;152:4039-4045.
58. Shao W, Yeretssian G, Doiron K, Hussain SN, Saleh M. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem 2007;282:36321-36329.
59. Tchkonia T, et al. Fat tissue, aging, and cellular senescence. Aging Cell 2010;9:667-684.
60. Baker DJ, et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011;479:232-236.
61. Riggs BL, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest 1982;70:716-723.
62. Mohler MJ, Fain MJ, Wertheimer AM, Najafi B, Nikolich-Zugich J. The Frailty syndrome: clinical measurements and basic underpinnings in humans and animals. Exp Gerontol 2014;54:6-13.
63. Colon-Emeric CS. Recent advances: osteoporosis in the "oldest old". Curr Osteoporo Rep 2013;11:270-275.
64. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-3325.
65. Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 2007;37:145-152.
66. Bonar SL, et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS ONE 2012;7:e35979.
67. Miller RA, Kreider J, Galecki A, Goldstein SA. Preservation of femoral bone thickness in middle age predicts survival in genetically heterogeneous mice. Aging Cell 2011;10:383-391.
68. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;469:221-225.
69. Dai DF, Chiao YA, Marcinek DJ, Szeto HH, Rabinovitch PS. Mitochondrial oxidative stress in aging and healthspan. Longev Healthspan 2014;3:6.
70. Marino G, Pietrocola F, Madeo F, Kroemer G. Caloric restriction mimetics: natural/physiological pharmacological autophagy inducers. Autophagy 2014;10:1879-1882.
71. Shi CS, et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012;13:255-263.
72. Shin JN, Fattah EA, Bhattacharya A, Ko S, Eissa NT. Inflammasome activation by altered proteostasis. J Biol Chem 2013;288:35886-35895.
73. Vilchez D, Saez I, Dillin A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat Commun 2014;5:5659.
74. Youm YH, et al. Ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015;PMID 25686106. [Epub ahead of print].
75. Yan Y, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 2013;38:1154-1163.
76. Edwards C, Canfield J, Copes N, Rehan M, Lipps D, Bradshaw PC. D-beta-hydroxybutyrate extends lifespan in C. elegans. Aging 2014;6:621-644.
77. Masoro EJ. Subfield history: caloric restriction, slowing aging, and extending life. Sci Aging Knowledge Environ 2003;2003:RE2.
78. Masino SA, Ruskin DN. Ketogenic diets and pain. J Child Neurol 2013;28:993-1001.
79. Shimazu T, et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013;339:211-214.
80. Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013;38:1142-1153.
81. Lu A, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 2014;156:1193-1206.
82. Snodgrass RG, Huang S, Choi IW, Rutledge JC, Hwang DH. Inflammasome-mediated secretion of IL-1beta in human monocytes through TLR2 activation; modulation by dietary fatty acids. J Immunol 2013;191:4337-4347.
83. Williams-Bey Y, et al. Omega-3 free fatty acids suppress macrophage inflammasome activation by inhibiting NF-kappaB activation and enhancing autophagy. PLoS ONE 2014;9:e97957.
84. De Guzman JM, et al. Chronic caloric restriction partially protects against age-related alteration in serum metabolome. Age 2013;35:1091-1104.
85. Rochon J, et al. Design and conduct of the CALERIE study: comprehensive assessment of the long-term effects of reducing intake of energy. J Gerontol A Biol Sci Med Sci 2011;66:97-108.
86. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA 2004;101:6659-6663.
87. Wright SD, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000;191:1437-1442.
88. Yang H, et al. Obesity accelerates thymic aging. Blood 2009;114:3803-3812.
89. Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity 2015;23:512-518.
90. Global Burden of Disease Study 2010. Institute for Health Metrics and Evaluation. University of Washington, Data Released March 2013. Available from http://vizhub.healthdata.org/gbd-compare/.